We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based T3D Therapeutics has announced it has received a $9m grant over four years from the US National Institutes of Health (NIH)’s National Institute of Aging to support its Phase II clinical trial of its lead candidate T3D-959 in Alzheimer’s disease.